Genzyme’s franchise products (Cerezyme, Renagel) continue to enjoy a majority market share in their niche markets, while new treatments (Myozyme, Synvisc) are being introduced in large, profitable markets.
Top Contributor: H JK | Created when NASDAQ:GENZ was $49.16 | Edit | History
This stock has taken quite a hit lately due to FDA inquiries about one of their major plants. Although this hurts the stock price now, most biotech companies are looked at with respect to pipeline. Near term earnings are very hard to forecast especially with biotech. This event is one of the reasons. It is also one of the reasons it looks attractive.